Exploring the Burden of Disease and Health Care Disparities in Anemia in Chronic Kidney Disease: A Review for Pharmacists

Add-on activity

This activity includes expert vignette videos.

Program Description

The burden of anemia associated with chronic kidney disease (CKD) is substantial due to treatment challenges and disease complications affecting ideal management in this patient population. Considerations of when to initiate treatment, choice of medication, and laboratory targets as goals of therapy to minimize adverse effects (AEs) of therapy influence treatment decisions in the multidisciplinary management of anemia in CKD. Research has also shown that racial and ethnic minorities have increased rates of CKD, a higher prevalence of early CKD, and a more rapid decline in renal function. As medication experts, pharmacists should be knowledgeable about the emerging new agents and medication regimens to prevent undertreatment of anemia in CKD across patient populations. This activity will review the pathophysiology of anemia in CKD as well as pharmacist-led strategies to limit AEs, address health care disparities, and ensure appropriate access to care for patients experiencing anemia in CKD. Expert video vignettes featuring an interview with a clinical specialist will accompany this article and offer practical information and advice on the management of patients who are at risk for anemia and diagnosed with CKD, along with patient counseling points.

Target audience: Health-system, retail, specialty pharmacists

Type of activity: Application
Release date: March 6, 2023
Expiration date: March 6, 2024

Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the burden of disease, clinical challenges, and data on untreated/undertreatment for anemia in chronic kidney disease (CKD)
• Illustrate the pathophysiology of anemia in CKD and emerging targets for treatment
• Differentiate the health care disparities in the management of anemia in CKD and the role of pharmacists to address these disparities

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-23-027-H01-P. The activity is available for CE credit through March 6, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Interview Video Faculty

Calvin J. Meaney, PharmD, BCPS, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Wolters Kluwer

Speakers Bureau: GlaxoSmithKline

Advisory Board: GlaxoSmithKline

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Laura H. Waite, PharmD, BCPS, CLS

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Karleen Rush, PharmD; Lauren Assennata; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms